Illumina (NASDAQ:ILMN) Stock Jumps 5% – What’s Next?

Illumina, Inc. (NASDAQ:ILMN)’s stock price traded up 5% during trading on Thursday. The company traded as high as $267.30 and last traded at $268.1350. Approximately 364,698 shares were traded during trading, a decline of 83% from the average session volume of 2,099,195 shares. The stock had previously closed at $255.38.

Key Headlines Impacting Illumina

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Raised outlook and business momentum: Illumina’s second-quarter results included better-than-expected earnings and revenue, with full-year 2026 revenue guidance raised to approximately $4.60 billion-$4.64 billion. Growth in sequencing, clinical adoption and demand outside Greater China are key factors behind the rally. Illumina Stock Surges 94.9% YTD: What’s Behind the Rally?
• Positive Sentiment: Recent S&P 500 inclusion: Illumina’s addition to the S&P 500 became effective September 21 and may have generated mechanical buying from index funds and other benchmarked investors. The company’s share repurchases, including roughly $122 million during the quarter, may also be supporting per-share results. Illumina gains as recent index inclusion and stronger outlook appear to support shares
• Positive Sentiment: Strong momentum: Reports highlight substantial year-to-date and 30-day gains, with Illumina recently reaching a new 52-week high as investors continue to favor the company’s growth prospects. Biotech Stocks At 52-Week Highs
• Neutral Sentiment: Index reshuffling: Illumina’s removal from the Russell Small Cap Value Index could create mechanical selling, although the effect may be offset by its recent S&P 500 inclusion. The reshuffle is also prompting investors to reassess the stock’s valuation. Illumina Tests Valuation As Russell Index Removal Forces A Fresh Look
• Negative Sentiment: Valuation and insider-selling concerns: After its steep advance, Illumina trades well above several recent analyst price targets, while reported insider activity shows sales but no open-market purchases. These factors could limit further gains or encourage profit-taking.
• Negative Sentiment: China remains a headwind: Despite stronger overall guidance, ongoing weakness or uncertainty in Greater China remains a risk to revenue growth and investor expectations.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on ILMN. Wall Street Zen raised Illumina from a “hold” rating to a “buy” rating in a research note on Saturday, August 1st. Barclays lifted their target price on Illumina from $145.00 to $160.00 and gave the company an “underweight” rating in a research note on Friday, July 31st. Weiss Ratings reissued a “hold (c)” rating on shares of Illumina in a report on Monday, August 31st. Piper Sandler restated an “overweight” rating and issued a $225.00 price target (up from $200.00) on shares of Illumina in a research note on Monday, August 3rd. Finally, Leerink Partners increased their price objective on shares of Illumina from $175.00 to $210.00 and gave the company an “outperform” rating in a report on Friday, July 17th. Ten analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $199.12.

Illumina Price Performance

The firm’s 50-day moving average price is $211.43 and its 200-day moving average price is $170.28. The company has a current ratio of 1.80, a quick ratio of 1.40 and a debt-to-equity ratio of 0.53. The stock has a market capitalization of $40.77 billion, a PE ratio of 50.37, a PEG ratio of 3.88 and a beta of 1.46.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, topping the consensus estimate of $1.23 by $0.08. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The company had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.13 billion. During the same quarter last year, the business posted $1.19 earnings per share. The firm’s revenue was up 9.4% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, equities analysts forecast that Illumina, Inc. will post 5.36 EPS for the current fiscal year.

Insider Activity at Illumina

In other news, Director Keith Meister sold 457,858 shares of Illumina stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $200.10, for a total value of $91,617,385.80. Following the completion of the transaction, the director owned 2,372,694 shares in the company, valued at approximately $474,776,069.40. The trade was a 16.18% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last three months, insiders sold 2,061,850 shares of company stock valued at $436,479,102. 2.90% of the stock is currently owned by insiders.

Institutional Trading of Illumina

A number of institutional investors have recently bought and sold shares of ILMN. QRG Capital Management Inc. boosted its stake in shares of Illumina by 8.1% during the 2nd quarter. QRG Capital Management Inc. now owns 7,261 shares of the life sciences company’s stock worth $1,277,000 after purchasing an additional 546 shares during the period. Envestnet Portfolio Solutions Inc. raised its position in Illumina by 18.6% in the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 6,935 shares of the life sciences company’s stock worth $1,219,000 after purchasing an additional 1,090 shares during the period. Tidal Investments LLC raised its position in Illumina by 10.3% in the 2nd quarter. Tidal Investments LLC now owns 93,728 shares of the life sciences company’s stock worth $16,480,000 after purchasing an additional 8,726 shares during the period. MCF Advisors LLC raised its position in Illumina by 172.4% in the 2nd quarter. MCF Advisors LLC now owns 158 shares of the life sciences company’s stock worth $28,000 after purchasing an additional 100 shares during the period. Finally, National Pension Service lifted its stake in Illumina by 246.7% in the second quarter. National Pension Service now owns 369,856 shares of the life sciences company’s stock worth $65,032,000 after purchasing an additional 263,172 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors.

About Illumina

Illumina, Inc develops and manufactures genomic analysis technologies used by researchers, healthcare providers, pharmaceutical companies and other organizations. Its offerings include next-generation DNA sequencing systems, microarray platforms, consumables, laboratory services and bioinformatics software designed to help analyze genetic variation and biological functions.

The company’s sequencing instruments include systems for a range of applications and throughput levels, such as the NovaSeq, NextSeq, MiSeq and iSeq platforms.